The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

##STR00001##

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

##STR00001##

Provided are solid forms of 5-(halomethyl)furfural, including a crystalline form of 5-(chloromethyl)furfural. Provided are also methods for preparing solid forms of 5-(halomethyl)furfural by crystallization using certain solvents.

Provided are solid forms of 5-(halomethyl)furfural, including a crystalline form of 5-(chloromethyl)furfural. Provided are also methods for preparing solid forms of 5-(halomethyl)furfural by crystallization using certain solvents.

A compound is represented by the following general formula (I): (I) wherein each of Rf1 and Rf2 is, independently, F, CF3, C2F5, C3F7, or C4F9, with the proviso that if either of Rf1 and Rf2 is fluorine, then the other is not fluorine; Rf3 is F, CF3, C2F5, C3F7 or CF(CF3)2; Rf4 is F, CF3, C2F5, C3F7 or CF(CF3)2; and Rh is CH3 or C2H5.

##STR00001##

A compound is represented by the following general formula (I): (I) wherein each of Rf1 and Rf2 is, independently, F, CF3, C2F5, C3F7, or C4F9, with the proviso that if either of Rf1 and Rf2 is fluorine, then the other is not fluorine; Rf3 is F, CF3, C2F5, C3F7 or CF(CF3)2; Rf4 is F, CF3, C2F5, C3F7 or CF(CF3)2; and Rh is CH3 or C2H5.

##STR00001##

A compound is represented by the following general formula (I): (I) wherein each of Rf1 and Rf2 is, independently, F, CF3, C2F5, C3F7, or C4F9, with the proviso that if either of Rf1 and Rf2 is fluorine, then the other is not fluorine; Rf3 is F, CF3, C2F5, C3F7 or CF(CF3)2; Rf4 is F, CF3, C2F5, C3F7 or CF(CF3)2; and Rh is CH3 or C2H5. ##STR00001##